Back to search results

Light Therapy for Mild Cognitive Impairment

This study is testing whether a non-invasive brain stimulation technique called transcranial photobiomodulation (tPBM) can help people with mild cognitive impairment (MCI). The study uses a device called the Vielight Neuro RX-Duo, which delivers near-infrared light to the brain. Researchers want to see if this light therapy can improve how blood flows in the brain (neurovascular coupling) and boost cognitive function, like memory. You might be able to join if you are between 55 and 95 years old, speak English, and have MCI with certain brain imaging findings. The main goal is to see if the light therapy changes brain blood flow regulation over 12 weeks.

Study design
This study is interventional and plans to enroll 40 participants. It uses both an active Vielight Neuro RX-Duo device and a sham device that looks identical but doesn't emit light.
What's involved
You would participate in a 12-week intervention protocol, with visits from baseline to a follow-up visit.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from the baseline visit to a follow-up visit after completing the 12-week intervention protocol.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07651787

Using Light Therapy for Mild Cognitive Impairment

Recruiting
NAAges 55–95InterventionalTreatment
University of Oklahoma
~40 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulationSham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in cortical neurovascular coupling
Measured over From baseline visit to the follow-up visit after completing a 12 week intervention protocol

Conditions

Mild Cognitive Impairment (MCI)
Amyloid Pathology

Explore related trials

Mild cognitive disorder

NCT07651787

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Oklahoma Health Campus

    Oklahoma City, Oklahomastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Peter Mukli, MD, PhD · PRINCIPAL_INVESTIGATOR · Department of Neurosurgery, University of Oklahoma Health Campus, Oklahoma, USA

Who to contact

Peter Mukli
[email protected]
+1 (405) 271-8001 · ext. 37745
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age: 55-95 years of age
Clinical Dementia Rating (CDR) equal to 0.5 and/or Montreal Cognitive Assessment (MoCA) \<26 and ≥19
Adequate hearing and visual acuity to participate in the examinations
English speaker
Presence of cerebrovascular pathology confirmed by structural brain imaging method

Exclusion

Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer
Cerebrovascular accident other than TIA within 60 days prior to Visit 0
Diagnosis of amyloid angiopathy
Major psychiatric disease, including major depression not controlled on medications, alcohol or drug abuse
Neurodegenerative diseases, e.g: Parkinson's, any kind of dementia
Patients currently using commercial brain stimulation / neuromodulation device as part of a research study
Patients currently take dietary supplements with an expected cerebrovascular benefit such as NAD- or NR-supplementum, L-citrullin, urolithin
Unstable medical condition, including uncontrolled diabetes, chronic heart issues, heart failure, chronic obstructive pulmonary disease, hypertension uncontrolled by medication (\>160/100 mmHg)
Any other medical condition or medication which, in the opinion of investigator, would render the patient too unstable to complete the study protocol
Severe sensory deficits interfering with the testing

What this trial measures

  • Change in cortical neurovascular couplingFrom baseline visit to the follow-up visit after completing a 12 week intervention protocol

    Functional near infrared spectroscopy (fNIRS) and electroencephalography (EEG) will be performed during the cognitive n-back task. fNIRS approach generates data that represent a relative change in oxygenated and deoxygenated hemoglobin measured over the cortical brain tissues. EEG records electrical potential changes in the brain cortex. Neurovascular coupling will be evaluated as a change in oxy- and deoxy-hemoglobin between before and after treatment, normalized to change in EEG. The change in regression coefficient reflecting change in neurovascular coupling responses is a dimensionless measure.